Today: 14 June 2026
Browse Category

NASDAQ:GLMD 17 November 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals reported that a triple-drug combination of Aramchol, Stivarga, and metformin sharply increased tumor cell killing in GI cancer models. Shares jumped as much as 38.6% premarket and traded around $1.18 by afternoon, with volume exceeding 41 million shares. The company plans a Phase 1b trial at VCU Massey Comprehensive Cancer Center in early 2026. New U.S. patent applications have been filed for the combination.
17 November 2025
···

Stock Market Today

  • FTSE Renewable Energy Stocks Offer 10.1% and 9.8% Dividend Yields Amid Market Uncertainty
    June 14, 2026, 3:07 AM EDT. Renewable energy stocks on the FTSE, specifically Greencoat UK Wind (LSE:UKW) and Foresight Environmental Infrastructure (LSE:FGEN), are yielding 10.1% and 9.8% respectively, attracting income investors despite sector challenges. Regulatory uncertainty and high interest rates have dampened sentiment, but rising energy prices from Middle East conflicts could boost profits due to operating leverage, where fixed production costs mean higher prices translate to increased earnings. Greencoat recently reported power prices above expectations, and Foresight raised dividends for the 12th consecutive time. However, risks remain as both companies hedge significant cashflows, limiting upside, and upcoming government policy changes will lower electricity prices. Inflation and interest rate hikes could also squeeze margins and threaten dividend sustainability.

Latest articles

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

Kraft Heinz Shares Rally for Six Days—Is KHC a Buy Now?

14 June 2026
Kraft Heinz closed up 0.70% at $24.39, outpacing the S&P 500, as investors weighed its 6.6% dividend yield against falling organic sales, lower adjusted earnings, and cautious analyst targets; the next earnings update is seen as the key test for whether $600 million in marketing and R&D can revive growth and support the stock’s rebound.
Go toTop